mGluR5 Antagonists Block Tau Hyperphosphorylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tauopathies, such as parkinsonism-dementia, fail to effectively address abnormal hyperphosphorylation of tau, leading to neurodegeneration and dementia, due to the complex mechanisms involving protein kinases and phosphatases like PP2A, where BMAA's neurotoxic effects are not fully understood.
Innovation Solution
The use of metabotropic glutamate receptor 5 (mGluR5) antagonists to inhibit the PP2A signaling pathway, specifically by blocking the phosphorylation of PP2Ac at Tyr307, which is activated by BMAA, thereby reducing tau hyperphosphorylation and neurofibrillary degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for tauopathies are used, then general symptom management is provided, but abnormal hyperphosphorylation of tau cannot be effectively addressed
Solution Approach 1:
The patent identifies mGluR5 as an intermediary target in the signaling pathway. By blocking mGluR5 with antagonists, the complex downstream effects on PP2A phosphorylation and tau hyperphosphorylation are interrupted. This provides a reliable treatment approach by targeting a specific mediator rather than attempting to manage multiple symptoms of the complex pathway.
2Object-affected harmful factors
If BMAA exposure occurs, then neuronal injury is induced, but the mechanism of tau phosphorylation and toxicity remains unclear
Solution Approach 1:
The patent establishes a feedback mechanism in the signaling pathway: BMAA activates mGluR5, which leads to PP2A phosphorylation at Tyr307, resulting in tau hyperphosphorylation. By identifying this feedback loop, the patent provides measurable markers (mGluR5 activation, PP2A phosphorylation status) to detect and understand the molecular mechanism of BMAA toxicity, moving from unclear mechanisms to detectable molecular events.
3Reliability
If PP2A activity is compromised, then tau dephosphorylation is reduced, but the upstream cause involving mGluR5 activation is not addressed
Solution Approach 1:
The patent applies preliminary action by blocking mGluR5 activation before it can lead to PP2A phosphorylation and tau hyperphosphorylation. By using mGluR5 antagonists upfront, the pathway is prevented from progressing to the harmful state, rather than attempting to restore PP2A activity after compromise has occurred. This preliminary intervention maintains reliable tau phosphatase activity by preventing the upstream activating event.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mGluR5 antagonists effectively block BMAA-induced inhibition of PP2A, preventing tau hyperphosphorylation and neurodegeneration, offering a therapeutic target for tauopathies like parkinsonism-dementia and related disorders.
Implementation Method 1
the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr307 induced by the activation of metabotropic glutamate receptor 5 (mGluR5) leads to hyperphosphorylation of tau
Data Source
AI summary
The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr307 is induced by the activation of metabotropic glutamate receptor 5 (mGluR5) and leads to hyperphosphorylation of tau. The mGluR5-PP2A axis has a central role in neurofibrillary degeneration and thus is be a therapeutic target for the treatment of tauopathies.